GP2 and familial pancreatic carcinoma: It was not until 2020 that a groundbreaking study based on a meta-analysis of three genome-wide association study (GWAS) datasets comprising 2039 pancreatic cancer patients and 32,592 controls from Japan confirmed the relatively pivotal role of GP2 gene variants in pancreatic cancer [63].